> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Joint Panel to Meet on Drug Study for Treating Achondroplasia
- URL: https://www.fdaweb.com/joint-panel-to-meet-on-drug-study-for-treating-achondroplasia/
- Published: 2018-01-23T12:00:00.000Z
- Updated: 2026-09-14T23:16:33.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5140569

*Federal Register* notice: FDA has announced a 3/22 joint Pediatric Advisory Committee and Endocrinologic and Metabolic Drugs Advisory Committee meeting which is expected to discuss the major objectives of a Phase 3 drug development program indicated for treating children with achondroplasia. Study elements to be considered include : Evidence required to establish dose-response, study design, e.g., placebo control, study duration, intended population, e.g., infants and toddlers and older children and adolescents, and endpoints that have a clinically meaningful impact on the patient’s functional or psychological well-being. To view the notice, click [here](https://www.gpo.gov/fdsys/pkg/FR-2018-01-23/pdf/2018-01120.pdf?ref=fdaweb.com).